DCM
VIRX

Driehaus Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Driehaus Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,598
Closed -$1.1M – 622
2017
Q2 		$1.1M Buy
11,598
+1,295
+13% +$149K 0.04% 337
2017
Q1 		$1.48M Sell
10,303
-1,803
-15% -$258K 0.05% 315
2016
Q4 		$1.53M Buy
12,106
+2,757
+29% +$384K 0.05% 298
2016
Q3 		$1.43M Buy
9,349
+56
+0.6% +$7.9K 0.05% 313
2016
Q2 		$1.07M Sell
9,293
-162
-2% -$17.9K 0.04% 336
2016
Q1 		$1.07M Sell
9,455
-388
-4% -$58.8K 0.03% 362
2015
Q4 		$1.85M Buy
9,843
+4,145
+73% +$775K 0.06% 309
2015
Q3 		$969K Buy
5,698
+545
+11% +$197K 0.03% 355
2015
Q2 		$3.26M Buy
5,153
+2,082
+68% +$1.11M 0.11% 230
2015
Q1 		$1.58M Sell
3,071
-43
-1% -$21.7K 0.05% 365
2014
Q4 		$1.67M Buy
+3,114
New +$1.4M 0.07% 341
2013
Q3 		– Sell
-1,385
Closed -$1.51M – 528
2013
Q2 		$1.51M Buy
+1,385
New +$1.54M 0.07% 299

Other funds holding VIRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Driehaus Capital Management's VIRX Position: Q3 2017 in Review

Driehaus Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2017, closing a stake of 11,598 shares — an estimated $1.1M sold.

Driehaus Capital Management first reported a position in VIRX in Q2 2013 and held it in 12 quarters. The position peaked at $3.26M in Q2 2015. 35 funds tracked by Wall St. Rank hold VIRX as of Q3 2017.

  • Driehaus Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Driehaus Capital Management sold 11,598 Viracta Therapeutics, Inc. Common Stock shares in Q3 2017, an estimated $1.1M.
  • Driehaus Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
  • Driehaus Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $3.26M in Q2 2015.
  • 35 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2017.

Based on Driehaus Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.